Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accelerated Access Review

- PMLiVE

UK pharma launches legal challenge to NICE plans

Applies for judicial review of budget impact test

- PMLiVE

NICE broadens access to Alexion’s rare disease drug Strensiq

New deal offers NHS England a discount for the drug

National Institute for Health and Care Excellence NICE logo

NICE backs Lilly’s rheumatoid arthritis drug Olumiant

The drug will be used alongside methotrexate to treat adults with severe, active RA

Using insights to effect behaviour change

The days when medical communication simply aimed to raise awareness of clinical challenges are well and truly over. In recent years, we have seen a clear shift towards changing physicians’...

Lucid Group Communications Limited

- PMLiVE

NICE relents on Kadcyla after Roche pricing negotiations

HER2-positive breast cancer therapy to be made available on the NHS in England

- PMLiVE

NICE rejects Pfizer’s antibody drug for leukaemia

Trial shows no survival benefit from Besponsa compared to current treatment

- PMLiVE

Spotlight on Events

Porterhouse has delivered many successful global programmes in 2017 so far. Read about our dedicated events team ...

Porterhouse Medical Group

- PMLiVE

All five of Lucid’s entries reach the shortlist for Communiqué 2017

Lucid Group is thrilled to learn that all its entries for the 2017 Communiqué Awards have been shortlisted as finalists! The categories include: Communications Consultancy of the Year Lucid Group   Excellence in Communications via...

Lucid Group Communications Limited

16 Generation Now

The impact of the millennial healthcare professional on our world

Havas Lynx

Your career starts here

When working in medical communications, one of the most common questions we get asked is “What is it that you actually do?” Many students and graduates are unaware of medical...

Lucid Group Communications Limited

- PMLiVE

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

Lucid Group Communications Limited

- PMLiVE

Cancer Drugs Fund “may have harmed patients”

Researchers claim most CDF drugs failed to show benefits to patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links